The world’s first allogeneic T-cell therapy — a type of universal immunotherapy treatment that relies on donor blood — was approved in Europe earlier this month. This is a game changer for medicine. It is also a game changer for the logistics industry.
While decentralized trails seem like a win-win-win, one of the biggest concerns surrounding this model is the safety and integrity of the drug when it is shipped to the patient’s home. This direct-to-patient model relies on a robust logistics strategy to support product viability and security.
All cell and gene therapies are composed of living cells with limited life spans, making it crucial that they are transported on time and in pristine condition.
FreightWaves’ journalist Matt Blois chats with World Courier’s Alex Guite about how the COVID-19 pandemic has impacted the cold chain and how pharma and logistics companies adapted to distribute vaccines.
On this episode of Medically Necessary, Matt Blois looks at how the pandemic shifted the way researchers conduct clinical trials.
Ray Wood, head of global carrier management at World Courier, discusses how the air cargo market has adjusted and maintained relationships with customers.
The past two years have seen unprecedented volatility across freight markets globally, with everything from weather events and the Suez Canal debacle to the pandemic impacting decision-making for carriers, shippers […]
The traditional silo model of suppliers using localized logistics providers is no longer working.
“We will surely see more local manufacturing in the future due to reshoring activities,” said Engel.
“In order to better position the product, you have to be closer to your patient,” House said.
A CFO, government affairs VP and two life science sales directors are hired and a Florida Customs Brokers & Forwarders Association board appointment is announced.
